Studying Cancer Therapy Resistance Mechanisms in Humans and Preclinical Models

We use well annotated clinical databases paired with prospectively collected patient tumor banks and state of the art sequencing technologies to perform high quality translational research in solid tumors. Our tumor bank includes longitudinal samples collected before and during radiation and chemotherapy, which allows us to ask important questions about how cancer therapies are impacting tumor cells and the tumor microenvironment.  We take these observations, derived directly from patient data, to the bench to conceptualize, optimize and test novel drug and radiotherapy combinations, which are then moved forward in the context of investigator-initiated clinical trials.

Learn more about our research »

WE’RE HIRING!

Schwarz lab is growing. We are currently recruiting post docs and staff scientists to join our group in support of newly funded grants. Applicants with experience in tumor immunology, metabolism and mouse genetics are encouraged to apply. We are actively recruiting graduate students (PhD and MSTP) and are open for rotations for fall and spring. We are a highly collaborative and fun group studying pancreas and ovarian cancer in addition to HPV related cancers. Please click the link above for job listing or email jschwarz@wustl.edu for details.

Schwarz presents at International Conference on Tumor Microenvironment and Cellular Stress

Schwarz presents at International Conference on Tumor Microenvironment and Cellular Stress

Julie Schwarz, MD, PhD, presented her research in Paphos, Cyprus on November 1, 2024. Her abstract: The combination of radiation therapy (RT) and immune checkpoint blockade (ICB) increases anti-tumor immunity; however, not all patients and tumors respond to this combination. RT has well known immune suppressive effects including stimulating the expression of chemokines and cytokines […]
Schwarz given FASTRO designation

Schwarz given FASTRO designation

Recognizing exceptional service to radiation oncology & cancer care as a whole, ASTRO professionals recently voted to confer upon Dr. Schwarz the designation of Fellow. She received this in Washington, D.C. in October, 2024, during ASTRO’s 66th Annual Meeting. Shown here in this photo with other female Fellow designees.